Enserink, J. M. et al. A novel Epac-specific cAMP analogue demonstrates independent regulation of Rap1 and ERK. Nature Cell. Biol. 4, 901-906

University of Bergen, Bergen, Hordaland, Norway
Nature Cell Biology (Impact Factor: 20.06). 12/2002; 4(11):901-6. DOI: 10.1038/ncb874
Source: PubMed

ABSTRACT cAMP is involved in a wide variety of cellular processes that were thought to be mediated by protein kinase A (PKA). However, cAMP also directly regulates Epac1 and Epac2, guanine nucleotide-exchange factors (GEFs) for the small GTPases Rap1 and Rap2 (refs 2,3). Unfortunately, there is an absence of tools to discriminate between PKA- and Epac-mediated effects. Therefore, through rational drug design we have developed a novel cAMP analogue, 8-(4-chloro-phenylthio)-2'-O-methyladenosine-3',5'-cyclic monophosphate (8CPT-2Me-cAMP), which activates Epac, but not PKA, both in vitro and in vivo. Using this analogue, we tested the widespread model that Rap1 mediates cAMP-induced regulation of the extracellular signal-regulated kinase (ERK). However, both in cell lines in which cAMP inhibits growth-factor-induced ERK activation and in which cAMP activates ERK, 8CPT-2Me-cAMP did not affect ERK activity. Moreover, in cell lines in which cAMP activates ERK, inhibition of PKA and Ras, but not Rap1, abolished cAMP-mediated ERK activation. We conclude that cAMP-induced regulation of ERK and activation of Rap1 are independent processes.

Download full-text


Available from: Jorrit Enserink, Aug 22, 2015
  • Source
    • "To investigate the role of cAMP-dependent protein kinases in the Iso mediated reduction in HDMEC motility, an inhibitor of PKA (rp cAMP (rp)) and an EPAC activator (8-CPT-2 0 -O- Me-cAMP (8-pCPT)) were used. 8-pCPT is a selective agonist for EPAC1 (Enserink et al., 2002) that activates EPAC1 with a higher affinity (EC 50 2.2 mM) than cAMP (EC 50 30 mM) but has no effect on PKA (Enserink et al., 2002). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Angiogenesis is an essential process during tissue regeneration; however, the amount of angiogenesis directly correlates with the level of wound scarring. Angiogenesis is lower in scar-free fetal wounds while angiogenesis is raised and abnormal in pathophysiological scarring such as hypertrophic scars and keloids. Delineating the mechanisms that modulate angiogenesis and could reduce scarring would be clinically useful. Beta-adrenoceptors (β-AR) are G protein-coupled receptors expressed on all skin cell-types. They play a role in wound repair but their specific role in angiogenesis is unknown. In this study, a range of in vitro assays (single cell migration, scratch wound healing, ELISAs for angiogenic growth factors and tubule formation) were performed with human dermal microvascular endothelial cells (HDMEC) to investigate and dissect mechanisms underpinning β-AR-mediated modulation of angiogenesis in chick chorioallantoic membranes (CAM) and murine excisional skin wounds. β-AR activation reduced HDMEC migration via cAMP-dependent and PKA-independent mechanisms as demonstrated through use of an EPAC agonist that auto-inhibited the cAMP-mediated β-AR transduced reduction in HDMEC motility; a PKA inhibitor was, conversely, ineffective. ELISA studies demonstrated that β-AR activation reduced pro-angiogenic growth factor secretion from HDMECs (fibroblast growth factor 2) and keratinocytes (vascular endothelial growth factor A) revealing possible β-AR-mediated autocrine and paracrine anti-angiogenic mechanisms. In more complex environments, β-AR activation delayed HDMEC tubule formation and decreased angiogenesis both in the CAM assay and in murine excisional skin wounds in vivo. β-AR activation reduced HDMEC function in vitro and angiogenesis in vivo; therefore, β-AR agonists could be promising anti-angiogenic modulators in skin. J. Cell. Physiol. © 2014 Wiley Periodicals, Inc.
    Journal of Cellular Physiology 02/2015; 230(2). DOI:10.1002/jcp.24716 · 3.87 Impact Factor
  • Source
    • "c o m / l o c a t e / m c e higher than that for PKA (Enserink et al., 2002), recent data indicate that Epac and PKA have similar affinity for cAMP, suggesting that physiological relevant cAMP concentrations are able to activate both enzymes (Dao et al., 2006). By using cAMP analogs that selectively activate Epac or PKA (Christensen et al., 2003; Enserink et al., 2002; Holz et al., 2008) it was possible to assess relative roles of PKA and Epac in mediating the effects of cAMP in several cell systems . To date, few data are available on the specific role of Epac in pituitary cells, the only observation suggesting its involvement on a-MSH release and ERK1/2 activation in mouse melanotrophs and AtT20 cell line, respectively (Sedej et al., 2005; Van Kolen et al., 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: In the pituitary the activation of cyclic adenosine 3'-5'-monophosphate (cAMP) dependent pathways generates proliferative signals in somatotrophs, whereas in pituitary cells of other lineages its effect remains uncertain. Moreover, the specific role of the two main cAMP effectors, protein kinase A (PKA) and Exchange Proteins directly Activated by cAMP (Epac), has not been defined. Aim of this study was to investigate the effect of cAMP on pituitary adenomatous cells proliferation and to identify PKA and Epac differential involvement. We found that cAMP increased DNA synthesis and cyclin D1 expression in somatotropinomas, whereas it reduced both parameters in prolactinomas and nonfunctioning adenomas, these effects being replicated in corresponding cell lines. Moreover, the divergent cAMP effects were mimicked by Epac and PKA analogs, which activated Rap1 and CREB, respectively. In conclusion, we demonstrated that cAMP exerted opposite effects on different pituitary cell types proliferation, these effects being mediated by both Epac and PKA.
    Molecular and Cellular Endocrinology 12/2013; 383(1-2). DOI:10.1016/j.mce.2013.12.006 · 4.24 Impact Factor
  • Source
    • "Reagents. 8-(4-Chlorophenylthio)-29-O-methyladenosine-39,59-cy- clic monophosphate, acetoxymethyl ester (007-AM), initially provided by and subsequently purchased from BioLog Life Science Institute (Bremen, Germany), is the highly membrane-permeant and potent acetoxymethyl ester prodrug (Vliem et al., 2008; Chepurny et al., 2009) of 8-(4-chlorophenylthio)-29-O-methyladenosine-39,59-cyclic monophosphate (007), the first selective EPAC agonist that is more than 100-fold less potent for PKA (Enserink et al., 2002; Christensen et al., 2003). After cell penetration of the uncharged prodrug, the active parental compound 007 is released by endogenous esterases and trapped inside the cell due to the negatively charged cyclic phosphate moiety. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The pleiotropic second-messenger cAMP plays a crucial role in mediating the effects of various hormones on metabolism. The major intracellular functions of cAMP are transduced by protein kinase A (PKA) and by exchange proteins directly activated by cAMP (EPACs). The latter act as guanine-nucleotide exchange factors for the RAS-like small G proteins Rap1 and Rap2. Although the role of PKA in regulating energy balance has been extensively studied, the impact of EPACs remains relatively enigmatic. This review summarizes recent genetic and pharmacological studies concerning EPAC involvement in glucose homeostasis and energy balance via the regulation of leptin and insulin signaling pathways. In addition, the development of small-molecule EPAC-specific modulators and their therapeutic potential for the treatment of diabetes and obesity are discussed.
    Trends in Endocrinology and Metabolism 11/2013; 25(2). DOI:10.1016/j.tem.2013.10.004 · 8.87 Impact Factor
Show more